IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:IOVA • US4622601007

2.6 USD
0 (0%)
At close: Feb 10, 2026
2.62 USD
+0.02 (+0.77%)
After Hours: 2/10/2026, 4:03:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

IOVA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. IOVA has a bad profitability rating. Also its financial health evaluation is rather negative. IOVA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • IOVA had negative earnings in the past year.
  • In the past year IOVA has reported a negative cash flow from operations.
  • In the past 5 years IOVA always reported negative net income.
  • In the past 5 years IOVA always reported negative operating cash flow.
IOVA Yearly Net Income VS EBIT VS OCF VS FCFIOVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

  • IOVA has a Return On Assets (-43.94%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -56.62%, IOVA is in the better half of the industry, outperforming 63.86% of the companies in the same industry.
Industry RankSector Rank
ROA -43.94%
ROE -56.62%
ROIC N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
IOVA Yearly ROA, ROE, ROICIOVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • Looking at the Gross Margin, with a value of 23.96%, IOVA is in the better half of the industry, outperforming 72.28% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for IOVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOVA Yearly Profit, Operating, Gross MarginsIOVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IOVA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IOVA has been increased compared to 5 years ago.
  • Compared to 1 year ago, IOVA has an improved debt to assets ratio.
IOVA Yearly Shares OutstandingIOVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IOVA Yearly Total Debt VS Total AssetsIOVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • IOVA has an Altman-Z score of -1.92. This is a bad value and indicates that IOVA is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of IOVA (-1.92) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.00 indicates that IOVA is not too dependend on debt financing.
  • IOVA has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: IOVA outperforms 51.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.92
ROIC/WACCN/A
WACC12.43%
IOVA Yearly LT Debt VS Equity VS FCFIOVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • IOVA has a Current Ratio of 3.41. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
  • IOVA has a Current ratio (3.41) which is in line with its industry peers.
  • IOVA has a Quick Ratio of 3.00. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
  • IOVA has a worse Quick ratio (3.00) than 61.57% of its industry peers.
Industry RankSector Rank
Current Ratio 3.41
Quick Ratio 3
IOVA Yearly Current Assets VS Current LiabilitesIOVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • IOVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.13%, which is quite impressive.
  • Looking at the last year, IOVA shows a very strong growth in Revenue. The Revenue has grown by 175.62%.
EPS 1Y (TTM)20.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)175.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.2%

3.2 Future

  • The Earnings Per Share is expected to grow by 19.02% on average over the next years. This is quite good.
  • Based on estimates for the next years, IOVA will show a very strong growth in Revenue. The Revenue will grow by 41.94% on average per year.
EPS Next Y17%
EPS Next 2Y24.23%
EPS Next 3Y22.65%
EPS Next 5Y19.02%
Revenue Next Year58.86%
Revenue Next 2Y59.11%
Revenue Next 3Y56.69%
Revenue Next 5Y41.94%

3.3 Evolution

IOVA Yearly Revenue VS EstimatesIOVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
IOVA Yearly EPS VS EstimatesIOVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • IOVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IOVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOVA Price Earnings VS Forward Price EarningsIOVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOVA Per share dataIOVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IOVA's earnings are expected to grow with 22.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.23%
EPS Next 3Y22.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • IOVA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (2/10/2026, 4:03:01 PM)

After market: 2.62 +0.02 (+0.77%)

2.6

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-03
Inst Owners54.61%
Inst Owner Change-0.37%
Ins Owners0.32%
Ins Owner Change4.84%
Market Cap1.03B
Revenue(TTM)250.43M
Net Income(TTM)-397.63M
Analysts75.56
Price Target8.52 (227.69%)
Short Float %31.93%
Short Ratio10.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.45%
Min EPS beat(2)-13.7%
Max EPS beat(2)8.8%
EPS beat(4)2
Avg EPS beat(4)-11.94%
Min EPS beat(4)-47.45%
Max EPS beat(4)8.8%
EPS beat(8)5
Avg EPS beat(8)-4.19%
EPS beat(12)9
Avg EPS beat(12)3.75%
EPS beat(16)11
Avg EPS beat(16)2.89%
Revenue beat(2)0
Avg Revenue beat(2)-12.22%
Min Revenue beat(2)-15.78%
Max Revenue beat(2)-8.66%
Revenue beat(4)0
Avg Revenue beat(4)-16.36%
Min Revenue beat(4)-40.82%
Max Revenue beat(4)-0.2%
Revenue beat(8)2
Avg Revenue beat(8)-20.87%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.01%
EPS NY rev (1m)0%
EPS NY rev (3m)7.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.12
P/FCF N/A
P/OCF N/A
P/B 1.47
P/tB 2.47
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0.63
BVpS1.77
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.94%
ROE -56.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.96%
FCFM N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 76.09%
Cap/Sales 11.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.41
Quick Ratio 3
Altman-Z -1.92
F-Score4
WACC12.43%
ROIC/WACCN/A
Cap/Depr(3y)118.96%
Cap/Depr(5y)1133.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y17%
EPS Next 2Y24.23%
EPS Next 3Y22.65%
EPS Next 5Y19.02%
Revenue 1Y (TTM)175.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.2%
Revenue Next Year58.86%
Revenue Next 2Y59.11%
Revenue Next 3Y56.69%
Revenue Next 5Y41.94%
EBIT growth 1Y6.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.44%
EBIT Next 3Y17.19%
EBIT Next 5YN/A
FCF growth 1Y6.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.11%
OCF growth 3YN/A
OCF growth 5YN/A

IOVANCE BIOTHERAPEUTICS INC / IOVA FAQ

What is the fundamental rating for IOVA stock?

ChartMill assigns a fundamental rating of 2 / 10 to IOVA.


What is the valuation status for IOVA stock?

ChartMill assigns a valuation rating of 1 / 10 to IOVANCE BIOTHERAPEUTICS INC (IOVA). This can be considered as Overvalued.


How profitable is IOVANCE BIOTHERAPEUTICS INC (IOVA) stock?

IOVANCE BIOTHERAPEUTICS INC (IOVA) has a profitability rating of 1 / 10.


Can you provide the financial health for IOVA stock?

The financial health rating of IOVANCE BIOTHERAPEUTICS INC (IOVA) is 3 / 10.